The new oral anticoagulants in clinical practice

Research output: Contribution to journalReview article

63 Citations (Scopus)

Abstract

Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug Administration approval of new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, clinicians now have a broader choice. Given the recent approval and availability of these medications, several questions arise while deciding which of them would be best suited for a particular patient. This article provides a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of these drugs, their pharmacokinetic and pharmacodynamic properties, and a practical approach to their clinical use. For this review, we conducted searches of PubMed and MEDLINE for articles published between January 1, 2000, and January 30, 2013, using the following search terms: oral anticoagulants, dabigatran, apixaban, rivaroxaban, novel anticoagulants, bleeding complications, management of bleeding complications, pharmacodynamics, and pharmacokinetics. Studies published in English were selected for inclusion in this review, as were additional articles identified from bibliographies.

Original languageEnglish (US)
Pages (from-to)495-511
Number of pages17
JournalMayo Clinic Proceedings
Volume88
Issue number5
DOIs
StatePublished - 2013

Fingerprint

Anticoagulants
Pharmacokinetics
Hemorrhage
Drug Approval
Vitamin K
Bibliography
United States Food and Drug Administration
PubMed
MEDLINE
Safety
Pharmaceutical Preparations
apixaban
Dabigatran
Rivaroxaban

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The new oral anticoagulants in clinical practice. / Gonsalves, Wilson; Pruthi, Rajiv K.; Patnaik, Mrinal M.

In: Mayo Clinic Proceedings, Vol. 88, No. 5, 2013, p. 495-511.

Research output: Contribution to journalReview article

@article{3f7320af147542a68df64b1e2ba49aed,
title = "The new oral anticoagulants in clinical practice",
abstract = "Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug Administration approval of new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, clinicians now have a broader choice. Given the recent approval and availability of these medications, several questions arise while deciding which of them would be best suited for a particular patient. This article provides a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of these drugs, their pharmacokinetic and pharmacodynamic properties, and a practical approach to their clinical use. For this review, we conducted searches of PubMed and MEDLINE for articles published between January 1, 2000, and January 30, 2013, using the following search terms: oral anticoagulants, dabigatran, apixaban, rivaroxaban, novel anticoagulants, bleeding complications, management of bleeding complications, pharmacodynamics, and pharmacokinetics. Studies published in English were selected for inclusion in this review, as were additional articles identified from bibliographies.",
author = "Wilson Gonsalves and Pruthi, {Rajiv K.} and Patnaik, {Mrinal M}",
year = "2013",
doi = "10.1016/j.mayocp.2013.03.006",
language = "English (US)",
volume = "88",
pages = "495--511",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - The new oral anticoagulants in clinical practice

AU - Gonsalves, Wilson

AU - Pruthi, Rajiv K.

AU - Patnaik, Mrinal M

PY - 2013

Y1 - 2013

N2 - Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug Administration approval of new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, clinicians now have a broader choice. Given the recent approval and availability of these medications, several questions arise while deciding which of them would be best suited for a particular patient. This article provides a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of these drugs, their pharmacokinetic and pharmacodynamic properties, and a practical approach to their clinical use. For this review, we conducted searches of PubMed and MEDLINE for articles published between January 1, 2000, and January 30, 2013, using the following search terms: oral anticoagulants, dabigatran, apixaban, rivaroxaban, novel anticoagulants, bleeding complications, management of bleeding complications, pharmacodynamics, and pharmacokinetics. Studies published in English were selected for inclusion in this review, as were additional articles identified from bibliographies.

AB - Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug Administration approval of new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, clinicians now have a broader choice. Given the recent approval and availability of these medications, several questions arise while deciding which of them would be best suited for a particular patient. This article provides a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of these drugs, their pharmacokinetic and pharmacodynamic properties, and a practical approach to their clinical use. For this review, we conducted searches of PubMed and MEDLINE for articles published between January 1, 2000, and January 30, 2013, using the following search terms: oral anticoagulants, dabigatran, apixaban, rivaroxaban, novel anticoagulants, bleeding complications, management of bleeding complications, pharmacodynamics, and pharmacokinetics. Studies published in English were selected for inclusion in this review, as were additional articles identified from bibliographies.

UR - http://www.scopus.com/inward/record.url?scp=84880149877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880149877&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2013.03.006

DO - 10.1016/j.mayocp.2013.03.006

M3 - Review article

C2 - 23639500

AN - SCOPUS:84880149877

VL - 88

SP - 495

EP - 511

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -